Cancer News and Research

Latest Cancer News and Research

HealthGrades identifies major flaws in hospital ratings study

HealthGrades identifies major flaws in hospital ratings study

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Online program helps people to manage chronic pain

Online program helps people to manage chronic pain

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Affymetrix launches new Axiom myDesign TG Arrays for targeted genotyping market

Affymetrix launches new Axiom myDesign TG Arrays for targeted genotyping market

Free NYU Physician iPad app now available in iTunes store

Free NYU Physician iPad app now available in iTunes store

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

Low calorie sweeteners offer effective solution to manage weight

Low calorie sweeteners offer effective solution to manage weight

Hospital websites use industry-provided content and overestimate claims of surgical robots

Hospital websites use industry-provided content and overestimate claims of surgical robots

Study: 10% of cancer patients fail to fill initial oral oncolytic prescriptions

Study: 10% of cancer patients fail to fill initial oral oncolytic prescriptions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.